Shares of Dyax Corp. (Nasdaq: DYAX) 44% HIGHER; announced positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). Statistically significant results were achieved for both the primary and secondary endpoints in the EDEMA3 trial.
Krispy Kreme Doughnuts, Inc. (NYSE: KKD) 5% LOWER; said revenues for the fourth quarter decreased 8.2% to $112.2 million compared to $122.2 million in the fourth quarter of last year. The net loss for the fourth quarter was $24.4 million, or $0.39 per diluted share, compared to a net loss of $37.7 million, or $0.61 per diluted share, in the comparable period last year. The net loss for the quarter includes a charge related to the settlement of litigation of approximately $16.0 million. The Company recorded a $2.1 million provision for doubtful accounts. The Company recorded a $1.3 million charge related to the proposed settlement of certain wage and hour complaints.
Sirius Satellite Radio Inc. (NASDAQ: SIRI) 2.3% HIGHER; XM Satellite Radio (Nasdaq: XMSR) received from the Department of Justice a request for additional information and documentary material relating to our merger with Sirius Satellite.
Merck’s (NYSE: MRK) 1% LOWER; FDA panel votes 20 to 1 against Merck’s Arcoxia pain reliever.
Planar Systems (NASDAQ: PLNR) INDICATED LOWER; expects Q2 sales to be $53-$54 million and Non-GAAP net loss per share to be $0.07 to $0.09. Past guidance was for sales of $57-$61 million and Non-GAAP net income per diluted share of $0.04 to $0.07 and GAAP net loss per share of $0.06 to $0.09.
Shares of Dyax Corp. (Nasdaq: DYAX) 44% HIGHER; announced positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). Statistically significant results were achieved for both the primary and secondary endpoints in the EDEMA3 trial.
Krispy Kreme Doughnuts, Inc. (NYSE: KKD) 5% LOWER; said revenues for the fourth quarter decreased 8.2% to $112.2 million compared to $122.2 million in the fourth quarter of last year. The net loss for the fourth quarter was $24.4 million, or $0.39 per diluted share, compared to a net loss of $37.7 million, or $0.61 per diluted share, in the comparable period last year. The net loss for the quarter includes a charge related to the settlement of litigation of approximately $16.0 million. The Company recorded a $2.1 million provision for doubtful accounts. The Company recorded a $1.3 million charge related to the proposed settlement of certain wage and hour complaints.
Sirius Satellite Radio Inc. (NASDAQ: SIRI) 2.3% HIGHER; XM Satellite Radio (Nasdaq: XMSR) received from the Department of Justice a request for additional information and documentary material relating to our merger with Sirius Satellite.
Merck’s (NYSE: MRK) 1% LOWER; FDA panel votes 20 to 1 against Merck’s Arcoxia pain reliever.
Planar Systems (NASDAQ: PLNR) INDICATED LOWER; expects Q2 sales to be $53-$54 million and Non-GAAP net loss per share to be $0.07 to $0.09. Past guidance was for sales of $57-$61 million and Non-GAAP net income per diluted share of $0.04 to $0.07 and GAAP net loss per share of $0.06 to $0.09.
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.